ROARABLE
FREE $100K
My Trading Account →
▾
Trading Account Active
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GELS / forecast
ADXN (48) PCSA (39) SCNX (28) LGVN (27) ⌘ Pro Terminal →

Gelteq Limited (GELS) 12-Month Stock Forecast & Price Target Cone

$0.49 -0.10% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.49

Gelteq Limited (GELS) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $5.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GELS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GELS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Gelteq Limited (NASDAQ: GELS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $0.49 (-0.10% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, GELS ranks #221 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GELS compare to ADXN and PCSA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GELS carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ADXN (Addex Therapeutics Ltd) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M) and PCSA (Processa Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, GELS leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GELS?
▼

For Gelteq Limited (GELS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #221 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.49 (-0.21%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510054
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Cash (12)Whales (11)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-2% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE GELS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GELS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY GELS SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($147.0K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$0.48-6.2% Next Q
Q2 (-2Q)
49
Grade D$0.45+2.2% Next Q
Q3 (-1Q)
51
Grade C-$0.46+6.5% Next Q
Current
54
Grade D+$0.49-0.7% Hist 90D α
Trajectory: D (46) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GELS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GELS currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.56) and Max Pain ($0.51) forces dealer call-delta covering toward $2.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GELS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GELS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your GELS Position Size: $10,000

Shares at $0.49: 20408.2 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.37
$7,551
$-2,449 (-24.5%)
12M Consensus BaseTarget $0.48
$9,796
$-204 (-2.0%)
12M Bull Case BreakoutTarget $2.11
$43,061
+$33,061 (+330.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 6
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$074%A
Goldman SachsSector Coverage LeadUNDERPERFORM$269%B
JP MorganUS Large-Cap ResearchSELL$058%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GELS)

  • ✓Walkthrough of GELS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GELS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.33%⚡ TESTING RESISTANCE
2026-11-03O $0.51H $0.51L $0.49C $0.49VOL 26.2K
RES: $0.50SUP: $0.43SMA50: $0.56SMA200: $0.65
$2.12$1.65$1.18$0.71$0.24RES $0.50SUP $0.43$0.492026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GELS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GELS Butterfly Map → + Track GELS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GELS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GELS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GELS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GELS)

Health Care Rank #221 of 1015 ⚔️ ADXN vs GELS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GELS vs. ADXN, PCSA, SCNX, LGVN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Gelteq Limited (GELS) ranks #221 by composite RQD confidence (54/100, grade D+) and #938 by equity capitalization ($5.2M). Within this direct 5-issuer industry benchmark cohort, GELS leads on earnings valuation at N/A trailing P/E, while PCSA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently leads its immediate peer cohort in composite quantitative strength at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GELS ACTIVE
Gelteq Limited
D+ 54/100 — — — -0.10% $5.2M Benchmark Subject
ADXN
Addex Therapeutics Ltd
D 48/100 — — — -3.24% $5.3M /adxn-vs-gels →
PCSA
Processa Pharmaceuticals Inc.
D- 39/100 — — -35.0% -2.12% $5.3M /pcsa-vs-gels →
SCNX
Scienture Holdings Inc.
E 28/100 — 76.8% -35.0% +0.31% $5.3M /scnx-vs-gels →
LGVN
Longeveron Inc. (Class A)
E 27/100 — 67.0% -35.0% +2.40% $5.3M /lgvn-vs-gels →

2. GELS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Gelteq Limited (GELS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $5.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. GELS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GELS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Gelteq Limited (NASDAQ: GELS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $0.49 (-0.10% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, GELS ranks #221 in composite RQD confidence.

How does GELS compare to ADXN and PCSA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GELS carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ADXN (Addex Therapeutics Ltd) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M) and PCSA (Processa Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, GELS leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GELS?

For Gelteq Limited (GELS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #221 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GELS trading relative to its 50-day, 200-day, and 52-week technical levels?

GELS last traded at $0.49 (-0.10% on volume of 9,126 shares), positioning the stock -12.50% below its 50-day simple moving average ($0.56) and -24.62% below its 200-day simple moving average ($0.65). Across its 52-week range of $0.39 to $2.01, GELS sits at the 6.2% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.55).

Direct Sub-Reports: GELS RQD Cockpit GELS 12M Forecast GELS Earnings & Move GELS Dividends & DRIP GELS Insiders & 13F GELS Whale Options GELS Profit Sankey GELS News & Why
ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ SEC XBRL & RQD VERIFIED

GELS — Gelteq Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Gelteq Limited (GELS) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $0.49 (-0.10% 1D, market capitalization $5.2M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Gelteq Limited (GELS) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..0B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 54/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 11/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $0.39 – $2.01 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The Butterfly Supply-Chain Graph reports no supply-chain relationships, no upstream or downstream dependencies, and no proprietary signals. Sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) is available, but sector correlation data and 2nd-order bottleneck information are not. The company-attribution question in the RISK WATCH news item also means that any ripple read from that item would be unverified.

  • Key Question #1: Can GELS sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $2.01 52-week high?
  • Key Question #3: How sensitive is GELS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GELS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Gelteq Limited (GELS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GELS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GELS Bull vs. Bear Conversation Board — What's Your Call at $0.49?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GELS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GELS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $0.60 (+22.4%)
📌 Pinned Debate

The balance sheet scores 13 of 20 with an Altman Z of 2.5 and Piotroski F of 6/9, the strongest pillar in the rating.

The street is overcomplicating Gelteq Limited (GELS). The balance sheet scores 13 of 20 with an Altman Z of 2.5 and Piotroski F of 6/9, the strongest pillar in the rating.. With an RQD score of 54/100 (D+) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.53.

EarningsSniper 🐂 BULL

Both sides have a point here — GELS's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $0.38 (-22.4%)
Spot @ $0.49

With ROIC at 0% and FCF yield at 0%, the stock's cash-generation engine scores only 12 of 20 and the rating verdict is Sell.

Careful chasing GELS at $0.49. With ROIC at 0% and FCF yield at 0%, the stock's cash-generation engine scores only 12 of 20 and the rating verdict is Sell.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.38 on multiple compression.

LIVE TAPE